Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System
Nov 1, 2015, 00:00
10.1016/j.jval.2015.09.055
https://www.valueinhealthjournal.com/article/S1098-3015(15)02131-2/fulltext
Title :
Cost-Utility Analysis of Natalizumab as First-Line Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis in the Brazilian Public Healthcare System
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(15)02131-2&doi=10.1016/j.jval.2015.09.055
First page :
A878
Section Title :
Research Podium Presentations - Session 1
Open access? :
No
Section Order :
2806